1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Not So Fast, Gene Editors

Ground-breaking Phase I Results For Gene Editing Light An Early Fuse

 
• By Andy Smith

Intellia’s announcement of the first in vitro gene editing proof of principle sent shockwaves through the life science investment space. But are there still many known unknowns.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

In a week when the merger of a neutron star and a black hole was reported to have disrupted the very fabric of space-time, the announcement of the first results of a successful in vivo gene editing study in humans elicited a seismic stock market shift back here on Earth. In contrast with cosmic events that occur millions of light years away, the time and risks from interim Phase I results to commercialization are prone to underestimation.

The recent conference presentation and journal publication of the first human data in six patients with hereditary transthyretin amyloidosis with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

More from Business

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.